Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2023 Oct 9;4(10):1526. doi: 10.1038/s43018-023-00663-3

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Isao Miyazaki 1,✉,#, Igor Odintsov 2,3,7,#, Keiji Ishida 1, Allan J W Lui 2,8, Masanori Kato 1, Tatsuya Suzuki 1, Tom Zhang 2, Kentaro Wakayama 1, Renate I Kurth 2, Ryan Cheng 2, Hidenori Fujita 1, Lukas Delasos 2,9, Morana Vojnic 2,3,10, Inna Khodos 4, Yukari Yamada 1, Kota Ishizawa 3,11, Marissa S Mattar 2, Kaoru Funabashi 1, Qing Chang 4, Shuichi Ohkubo 1, Wakako Yano 1, Ryuichiro Terada 1, Claudio Giuliano 5, Yue Christine Lu 2, Annalisa Bonifacio 5, Siddharth Kunte 2,12, Monika A Davare 6, Emily H Cheng 3, Elisa de Stanchina 4, Emanuela Lovati 5, Yoshikazu Iwasawa 1, Marc Ladanyi 2,3, Romel Somwar 2,3,✉
PMCID: PMC10597837  PMID: 37814012

Correction to: Nature Cancer 10.1038/s43018-023-00630-y, published online 21 September 2023.

In the version of the article initially published, the affiliation of Ryan Cheng was incorrect and has now been updated to the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, in the HTML and PDF versions of the article.

Contributor Information

Isao Miyazaki, Email: isao-miyazaki@taiho.co.jp.

Romel Somwar, Email: somwarr@mskcc.org.

Articles from Nature Cancer are provided here courtesy of Nature Publishing Group

RESOURCES